MedTrace Logo

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

NCT02303405 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-10-20

Study results available
· View outcomes & findings →

Summary

A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.

Conditions

  • Diabetes Mellitus Type 2 With Hyperglycemia

Interventions

DRUG

Hydroxychloroquine

Anti-inflammatory and anti-malarial agent

DRUG

Pioglitazone

Anti-hyperglycemic agent

Sponsors & Collaborators

  • Charles Drew University of Medicine and Science

    lead OTHER

Principal Investigators

  • Stanley H Hsia, MD · Charles Drew University of Medicine and Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303405 on ClinicalTrials.gov